RE:RE:The More I Search, the More Mind-Boggling the Adcom's Decis Of all the concerns here, I don't think misrepresentation is one of them. Unless you consider refusing to properly address the question at hand, within defined parameters provided by the FDA as a misrepresentation of objectivity? You guys seem knowledgeable. Far more than myself and others. while little was provided in the Telesta NR they did note that they will be consulting with Ipsen. What roll or rolls can we expect an Ipsen to play going forward with the FDA. Surely they the skill set and experience to provide guidance. Should Ipsen have had a rep there to provide a sense of strength and unity in behalf of Telsta from a marketplace perspective. Monique C. did as best as could be expected, but this was a French Canadian person representing a Canadian company. If some Advomm reps had not done their homework would Telesta have appeared very inconsequential and an easy target for some ego driven agendas? We need help and Ipsen has some brand name cache in Oncology as I have read.